CAR T cell therapy has shown remarkable therapeutic activity in patients with certain B-cell leukemias and lymphomas, and promising efficacy in multiple myeloma. However, various barriers limit its efficacy and widespread use, particularly in solid tumors. Key challenges include severe toxicities, limited tumor infiltration, suboptimal persistence, antigen escape, heterogeneity, and manufacturing issues. To address these, innovative CAR designs and engineering strategies are being developed to improve safety, efficacy, and applicability. CARs consist of four components: an antigen-binding domain, hinge, transmembrane domain, and intracellular signaling domain. The antigen-binding domain typically includes a single-chain variable fragment (scFv) derived from monoclonal antibodies. The hinge provides flexibility, while the transmembrane domain anchors the CAR in the T cell membrane. The intracellular signaling domain usually includes a CD3ζ-derived activation domain and co-stimulatory domains like CD28 or 4-1BB. To enhance CAR T cell efficacy, strategies are being developed to address challenges related to the unique biology of various malignancies. These include improving CAR design, optimizing antigen recognition, and reducing toxicities. For example, CD28 co-stimulatory domains may lead to faster activation and exhaustion, while 4-1BB domains may result in lower peak T cell expansion and reduced cytokine-mediated toxicities. To mitigate systemic cytokine toxicities, strategies such as using IL-6 pathway inhibitors, modifying CAR constructs to reduce immunogenicity, and engineering 'off switches' or 'suicide genes' are being explored. Additionally, approaches like using protease-based small molecule-assisted shutoff CARs (SMAShCARs) or apoptosis-triggering fusion proteins (e.g., iCasp9) allow for rapid deactivation of CAR T cells in case of toxicity. On-target, off-tumor toxicities occur when CAR T cells recognize antigens on non-malignant cells. Strategies to mitigate this include targeting multiple antigens, using logic-gated CARs, or modifying non-malignant tissues to remove the target antigen. For example, CRISPR-Cas9 has been used to knockout CD33 in non-malignant cells to prevent CAR T cell targeting of essential hematopoietic progenitor cells. To improve CAR T cell persistence, strategies focus on using T cell subsets with higher proliferative capacity, such as naive T cells, stem cell memory T cells, and central memory T cells. Infusing CAR T cells at a defined CD4+/CD8+ T cell ratio can enhance expansion and reduce toxicity. Overall, engineering strategies are being developed to enhance the safety, efficacy, and applicability of CAR T cell therapy across a broader range of malignancies. These include optimizing CAR design, reducing toxicities, and improving tumor homing and penetration. The future of CAR T cell therapy depends on continued innovation in these areas to overcome current limitations and expand its clinical utilityCAR T cell therapy has shown remarkable therapeutic activity in patients with certain B-cell leukemias and lymphomas, and promising efficacy in multiple myeloma. However, various barriers limit its efficacy and widespread use, particularly in solid tumors. Key challenges include severe toxicities, limited tumor infiltration, suboptimal persistence, antigen escape, heterogeneity, and manufacturing issues. To address these, innovative CAR designs and engineering strategies are being developed to improve safety, efficacy, and applicability. CARs consist of four components: an antigen-binding domain, hinge, transmembrane domain, and intracellular signaling domain. The antigen-binding domain typically includes a single-chain variable fragment (scFv) derived from monoclonal antibodies. The hinge provides flexibility, while the transmembrane domain anchors the CAR in the T cell membrane. The intracellular signaling domain usually includes a CD3ζ-derived activation domain and co-stimulatory domains like CD28 or 4-1BB. To enhance CAR T cell efficacy, strategies are being developed to address challenges related to the unique biology of various malignancies. These include improving CAR design, optimizing antigen recognition, and reducing toxicities. For example, CD28 co-stimulatory domains may lead to faster activation and exhaustion, while 4-1BB domains may result in lower peak T cell expansion and reduced cytokine-mediated toxicities. To mitigate systemic cytokine toxicities, strategies such as using IL-6 pathway inhibitors, modifying CAR constructs to reduce immunogenicity, and engineering 'off switches' or 'suicide genes' are being explored. Additionally, approaches like using protease-based small molecule-assisted shutoff CARs (SMAShCARs) or apoptosis-triggering fusion proteins (e.g., iCasp9) allow for rapid deactivation of CAR T cells in case of toxicity. On-target, off-tumor toxicities occur when CAR T cells recognize antigens on non-malignant cells. Strategies to mitigate this include targeting multiple antigens, using logic-gated CARs, or modifying non-malignant tissues to remove the target antigen. For example, CRISPR-Cas9 has been used to knockout CD33 in non-malignant cells to prevent CAR T cell targeting of essential hematopoietic progenitor cells. To improve CAR T cell persistence, strategies focus on using T cell subsets with higher proliferative capacity, such as naive T cells, stem cell memory T cells, and central memory T cells. Infusing CAR T cells at a defined CD4+/CD8+ T cell ratio can enhance expansion and reduce toxicity. Overall, engineering strategies are being developed to enhance the safety, efficacy, and applicability of CAR T cell therapy across a broader range of malignancies. These include optimizing CAR design, reducing toxicities, and improving tumor homing and penetration. The future of CAR T cell therapy depends on continued innovation in these areas to overcome current limitations and expand its clinical utility